Enliven Therapeutics, Inc. (ELVN) Stock

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. (ELVN) stock trades at $41.52 with a market capitalization of $3.04B. The stock is valued at a negative price-to-earnings (P/E) ratio of -27.91, reflecting a net loss over the last twelve months, price-to-book of 3.38, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $14.79 and $62.32, and currently trades 33.4% below its 52-week high.

On profitability, Enliven Therapeutics, Inc. generates a return on equity (ROE) of -18.55% (negative, reflecting a net loss), return on capital employed of -13.88%.

Enliven Therapeutics, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Enliven Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-104.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-106.0M.

Borrowings fell from $1.0M to $0, cash from operations was $-70.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -10.9% over five years, and was -22.6% in the most recent year.

The share price itself has compounded at 6.5% a year over five years, 29.7% over three, 122.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Enliven Therapeutics, Inc. (ELVN) — frequently asked questions